Status:
COMPLETED
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Carcinoma, Non-small-cell Lung
Eligibility:
All Genders
Brief Summary
This is a study of the safety and effectiveness of atezolizumab in participants with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing ...
Eligibility Criteria
Inclusion
- Signed an informed consent form submitted to the Administración Nacional de Medicamentos Alimentos y Tecnología Médica (ANMAT)
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) non-small cell lung cancer (NSCLC)
- Have received at least one dose of atezolizumab as per local label and clinical practice
Exclusion
- Contraindicated atezolizumab therapy
Key Trial Info
Start Date :
December 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 2 2019
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT03321695
Start Date
December 27 2017
End Date
March 2 2019
Last Update
March 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Productos Roche S.A. Quimica e Industrial, División Farmacéutica
Buenos Aires, Argentina, B1610BAL